Finance

Lists
Why is REMEDY up 4,39%?
Dive Deeper
REMEDY:HEL
Remedy Entertainment Oyj
€17,12
+4,39%
(+0,72) 1D
16 Okt., 18:16:29 GMT+3  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for REMEDY...
Open
€17,58
High
€19,14
Low
€17,12
Mkt. cap
233,52 m
Avg. vol.
21,22 k
Volume
74,74 k
52-wk high
€20,65
52-wk low
€11,06
EPS
-€1,17
Shares outstanding
13,64 m
No. of employees
379
Open
€17,58
High
€19,14
Low
€17,12
Mkt. cap
233,52 m
Avg. vol.
21,22 k
Volume
74,74 k
52-wk high
€20,65
52-wk low
€11,06
EPS
-€1,17
Shares outstanding
13,64 m
No. of employees
379
News stories
From web sources and news partners
Profile
Remedy Entertainment Oyj, trading internationally as Remedy Entertainment Plc, is a Finnish video game developer based in Espoo. Notable games the studio has developed include the first two entries in the Max Payne franchise, Alan Wake, Quantum Break, and Control. Sam Lake, Remedy's creative director, has represented the company on numerous occasions. Founded in August 1995 by members of demoscene group Future Crew, Remedy Entertainment created its first game, Death Rally, in a team member's basement. Apogee Software served as the game's publisher, and continued to be involved in the production of its next title, Max Payne, which received critical acclaim upon release. The game was followed by a sequel, Max Payne 2: The Fall of Max Payne, released by Rockstar Games. After spending seven years working on the Max Payne franchise, the developer decided to create a new intellectual property called Alan Wake. This title was once suspected to be vaporware because of the length of time it took to produce and release. It gained a cult following when it was released in 2010, by Microsoft Game Studios, though at the time its sales were not enough to justify the production of a sequel. Wikipedia
About Remedy Entertainment Oyj
CEO-
Employees379
Founded18 Aug. 1995
Headquarters-
Sector-
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
12,16 m
17,04 m
13,14 m
10,16 m
Cost of goods sold
2,40 m
4,23 m
907,00 k
1,15 m
Cost of revenue
2,40 m
4,23 m
907,00 k
1,15 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,84 m
9,52 m
6,34 m
6,74 m
Operating expense
26,18 m
-2,83 m
11,20 m
12,95 m
Total operating expenses
28,58 m
1,40 m
12,11 m
14,10 m
Operating income
-16,42 m
15,64 m
1,03 m
-3,94 m
Other non operating income
-
621,00 k
-
-1,00 k
EBT including unusual items
-16,70 m
453,00 k
752,00 k
-3,91 m
EBT excluding unusual items
-16,70 m
15,37 m
752,00 k
-3,91 m
Income tax expense
-3,24 m
52,00 k
276,00 k
-668,00 k
Effective tax rate
19,42%
11,48%
36,70%
17,08%
Other operating expenses
3,23 m
-565,00 k
2,96 m
4,66 m
Net income
-13,45 m
401,00 k
476,00 k
-3,24 m
Net profit margin
-110,68%
2,35%
3,62%
-31,94%
Earnings per share
-0,99
0,03
0,04
-0,24
Interest and investment income
271,00 k
40,00 k
13,00 k
488,00 k
Interest expense
-543,00 k
-703,00 k
-290,00 k
-455,00 k
Net interest expenses
-272,00 k
-663,00 k
-277,00 k
33,00 k
Depreciation and amortization charges
17,11 m
-11,78 m
1,90 m
1,55 m
EBITDA
-15,83 m
16,15 m
1,51 m
-3,46 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme